Another retrospective study showed that increased intratumoral CD8+ T cell infiltration and an increased CD8+ T cell/Treg ratio were linked to a better treatment response of recurrent/metastatic HNSCC patients who were treated with immunotherapy (Hanna et al., 2018). The gene discussed is CD8A; the disease is head and neck squamous cell carcinoma.